When is the next results date for Samrat Pharma?

No Upcoming Board Meetings

Who are in the management team of Samrat Pharma?

As of March 2022, the management team of Samrat Pharma includes Lalit Mehta (Chairman & Managing Director), Rajesh Mehta (Director & CFO), and four independent directors: Mahendra Pipalia, Samir Kothary, Renu P Dharod, along with Megh Mehta (Executive Director) and Nishant Kankaria (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2022, the management team of Samrat Pharma consists of the following individuals:<BR><BR>1. Lalit Mehta - Chairman & Managing Director<BR>2. Rajesh Mehta - Director & CFO<BR>3. Mahendra Pipalia - Independent Director<BR>4. Samir Kothary - Independent Director<BR>5. Renu P Dharod - Independent Director<BR>6. Megh Mehta - Executive Director<BR>7. Nishant Kankaria - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Samrat Pharma do?

Samrat Pharmachem Ltd manufactures and sells chemicals in the Pharmaceuticals & Biotechnology industry, operating as a Micro Cap company. As of March 2025, it reported net sales of 71 Cr and a market cap of Rs 110 Cr.

Overview:<BR>Samrat Pharmachem Ltd is engaged in the manufacturing and selling of chemicals within the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated on June 16, 1992. In the fiscal year 2003-04, it established a 100% subsidiary named Samrat Remedies Limited to focus on the manufacturing of Pharmaceutical Bulk Drugs & Chemicals. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 71 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 110 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 15.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.28%<BR>- Debt-Equity: -0.02<BR>- Return on Equity: 10.94%<BR>- Price to Book: 1.67<BR><BR>Contact Details:<BR>- Address: Plot No A2/3445, GIDC Phase IV Ankleshwar Gujarat : 393002<BR>- Tel: 91-2646-220774<BR>- Email: samrat@bom4.vsnl.net.in<BR>- Website: http://www.samratpharmachem.com

Has Samrat Pharma declared dividend?

Yes, Samrat Pharma has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 19, 2024. The dividend yield is 0.28%, and while long-term returns have been positive, short-term performance has shown mixed results.

Samrat Pharma has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.28%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.34%, with a dividend return of 0%, resulting in a total return of -13.34%.<BR><BR>Over the past year, the price return was 2.78%, with a dividend return of 0.30%, leading to a total return of 3.08%.<BR><BR>In the 2-year period, the price return was -15.92%, while the dividend return was 0.47%, resulting in a total return of -15.45%.<BR><BR>For the 3-year period, the price return was -26.15%, with a dividend return of 0.80%, culminating in a total return of -25.35%.<BR><BR>In the last 4 years, the price return was 38.41%, with a dividend return of 1.26%, giving a total return of 39.67%.<BR><BR>Over the 5-year period, the price return was 363.67%, with a dividend return of 3.57%, resulting in a total return of 367.24%.<BR><BR>Overall, while Samrat Pharma has declared a dividend, the total returns over various periods show a mixed performance, with significant gains over the long term but negative returns in shorter periods. The dividend yield remains relatively low at 0.28%.

Who are the peers of the Samrat Pharma?

Samrat Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Source Natural, Bharat Immunolog, Mercury Labs, and Makers Labs. Key insights show excellent management and growth for Sun Pharma, Cipla, and Dr Reddy's Labs, while Samrat Pharma has below-average growth and a 1-year return of -1.02%.

Peers: The peers of Samrat Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Source Natural, Bharat Immunolog, Mercury Labs, Makers Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Source Natural, and Mercury Labs, while Average management risk is found at Mercury Labs. Below Average management risk is noted for Bharat Immunolog, Makers Labs, and Ajooni Biotech. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Source Natural, Bharat Immunolog, Samrat Pharma, Mercury Labs, and Makers Labs. Excellent capital structure is held by Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Samrat Pharma, and Mercury Labs, while Good capital structure is found at Torrent Pharma and Source Natural, and Below Average capital structure is noted for Bharat Immunolog and Makers Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while Bharat Immunolog has the lowest at -9.56%. Samrat Pharma's 1-year return is -1.02%, which is higher than Bharat Immunolog's but lower than Divi's Lab.'s. Additionally, the six-month returns for Torrent Pharma, Source Natural, Mercury Labs, and Makers Labs are negative.

What is the technical trend for Samrat Pharma?

As of June 2, 2025, Samrat Pharma's technical outlook is mildly bearish, driven by bearish signals from moving averages and Bollinger Bands, despite some short-term strength indicated by the KST.

As of 2 June 2025, the technical trend for Samrat Pharma has changed from mildly bullish to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD is bearish, suggesting a divergence in time frames. The Bollinger Bands are bearish for both weekly and monthly periods, reinforcing the bearish outlook. Daily moving averages are also bearish, which adds to the negative sentiment. The KST shows a mildly bullish signal on the weekly but remains bullish on the monthly, indicating some strength in the short term. Dow Theory reflects a mildly bearish stance on the weekly, with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish signals from moving averages and Bollinger Bands.

Who are the top shareholders of the Samrat Pharma?

The top shareholder of Samrat Pharma is Lalit Damodar Mehta, holding 13.97%. Individual investors collectively own 41.58%, while the highest public shareholder is Sangeetha S at 3.27%.

The top shareholders of Samrat Pharma include the promoters, with Lalit Damodar Mehta holding the largest share at 13.97%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sangeetha S, who owns 3.27%. Additionally, individual investors collectively hold 41.58% of the company's shares.

How big is Samrat Pharma?

As of 24th July, Samrat Pharmachem Ltd has a market capitalization of 113.00 Cr, with recent net sales of 285.85 Cr and a net profit of 7.11 Cr. Shareholder's funds are 65.00 Cr, and total assets are valued at 121.74 Cr as of March 2024.

As of 24th July, Samrat Pharmachem Ltd has a market capitalization of 113.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 285.85 Cr and a Net Profit of 7.11 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 65.00 Cr and Total Assets valued at 121.74 Cr.

Are Samrat Pharma latest results good or bad?

Samrat Pharma's latest results are concerning, with a 43.57% decline in Profit After Tax and negative Profit Before Tax, leading MarketsMOJO to issue a 'Sell' call. Despite a slight increase in net sales, the overall financial performance remains weak, indicating significant challenges for the company.

The latest financial results for Samrat Pharmachem indicate significant challenges for the company. For the nine-month period, the Profit After Tax (PAT) has declined by 43.57%, totaling Rs 2.15 crore. This decline in profitability is concerning, especially as the Operating Profit Before Depreciation, Interest, and Taxes (PBDIT) has reached its lowest level in the last five quarters at Rs 0.12 crore. Additionally, the Profit Before Tax (PBT) has also turned negative, recorded at Rs -0.48 crore.<BR><BR>While there was a slight increase in net sales growth of 6.25% compared to the previous quarter, the overall financial performance remains flat, and the company is facing ongoing difficulties. In light of these results, MarketsMOJO has issued a 'Sell' call on Samrat Pharma, reflecting the negative outlook based on their current financial challenges. Overall, the results can be characterized as bad, indicating a need for the company to address its financial issues.

Should I buy, sell or hold Samrat Pharma?

How has been the historical performance of Samrat Pharma?

Samrat Pharma's historical performance shows fluctuating financial metrics, with net sales rising from INR 137.45 crore in March 2020 to a peak of INR 310.65 crore in March 2023, followed by a decline and slight recovery. Key indicators like operating profit and profit after tax also experienced significant volatility during this period.

Answer:<BR>The historical performance of Samrat Pharma shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Samrat Pharma's net sales increased from INR 137.45 crore in March 2020 to INR 285.86 crore in March 2025, with a peak of INR 310.65 crore in March 2023. However, there was a decline in net sales from March 2023 to March 2024, followed by a slight recovery in March 2025. The total operating income mirrored this trend, reaching INR 310.65 crore in March 2023 before dropping to INR 281.58 crore in March 2024 and rebounding to INR 285.86 crore in March 2025. The operating profit (PBDIT) saw significant fluctuations, peaking at INR 24.89 crore in March 2022, then dropping to INR 2.47 crore in March 2024, and recovering to INR 10.24 crore in March 2025. Profit after tax also exhibited volatility, with a high of INR 16.63 crore in March 2023, declining to INR 2.16 crore in March 2024, and then increasing to INR 7.11 crore in March 2025. The company's total assets grew from INR 58.35 crore in March 2020 to INR 121.49 crore in March 2025, while total liabilities remained relatively stable, peaking at INR 121.74 crore in March 2024. Cash flow from operating activities was negative in March 2025 at INR -10 crore, contrasting with a positive cash flow of INR 9 crore in March 2024. Overall, Samrat Pharma's financial performance reflects a mix of growth and challenges over the years.

Is Samrat Pharma overvalued or undervalued?

As of November 18, 2025, Samrat Pharma is considered overvalued with a PE Ratio of 53.48, significantly higher than its peers, and has experienced a poor year-to-date return of -29.33%, indicating a shift in market perception from very attractive to very expensive.

As of 18 November 2025, the valuation grade for Samrat Pharma has moved from very attractive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE Ratio of 53.48, an EV to EBITDA of 18.52, and a Price to Book Value of 1.18, all of which suggest that the stock is priced at a premium compared to its earnings and assets.<BR><BR>In comparison to its peers, Samrat Pharma's PE Ratio is notably higher than Sun Pharma's 36.56 and significantly exceeds Cipla's more attractive valuation at 22.49. Additionally, while the PEG Ratio stands at 0.00, indicating no growth expectations priced in, other competitors like Divi's Lab show a PEG of 1.96, reflecting a more balanced valuation. The company's recent stock performance has been poor, with a year-to-date return of -29.33%, contrasting sharply with the Sensex's gain of 8.36%, further reinforcing the notion that Samrat Pharma is overvalued in the current market environment.

Which are the latest news on Samrat Pharma?

Why is Samrat Pharma falling/rising?

As of 04-Dec, Samrat Pharmachem Ltd's stock price is Rs 252.00, reflecting a 3.78% decline. The stock has significantly underperformed the Sensex across various timeframes, with a year-to-date drop of 34.04% and a long-term decline of 64.75% over three years.

As of 04-Dec, Samrat Pharmachem Ltd's stock price is falling, currently at Rs 252.00, which reflects a decrease of Rs 9.9 or 3.78%. This decline is part of a broader trend, as the stock has underperformed significantly compared to the benchmark Sensex over various periods. For instance, over the past week, the stock has decreased by 1.29%, while the Sensex has only fallen by 0.53%. In the past month, the stock has dropped by 11.73%, contrasting with a 2.16% increase in the Sensex.<BR><BR>Year-to-date, the stock has seen a substantial decline of 34.04%, while the Sensex has gained 9.12%. Over the past year, the stock's performance has been even worse, with a drop of 37.93% compared to the Sensex's modest gain of 5.32%. The long-term trend is similarly negative, with a 64.75% decrease over the past three years, while the Sensex has increased by 35.62%.<BR><BR>Today's trading activity indicates a continuation of this downward trend, as the stock is only 2.78% away from its 52-week low of Rs 245. The stock has also underperformed its sector by 4.07% today and has fallen after two consecutive days of gains. The intraday low reached Rs 251.05, marking a decline of 4.14%. Additionally, the stock is trading below all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), which suggests a bearish trend. <BR><BR>Investor participation appears to be declining, with a delivery volume of 1.68k on December 3, which is down by 8.05% compared to the 5-day average. This lack of interest may contribute to the stock's falling price. Overall, the combination of poor performance relative to the market, negative trading trends, and declining investor participation are key factors driving the stock's current decline.